Tashkent, Uzbekistan (UzDaily.com) -- The Center for Advanced Technologies under the Ministry of Innovative Development of the Republic of Uzbekistan and the Research Institute of Virology of the Ministry of Health are conducting Phase III clinical trials of the ZF2001 recombinant vaccine produced by the Chinese company Anhui Zhifei Loncom Biofharmaceutical. 

The trial is expected to include 5,000 volunteers over 18 years of age who do not suffer from chronic diseases. Currently, along with the formation of the list of subjects, selected volunteers are injected with a single vaccine. Volunteers will be vaccinated with just three doses of the vaccine during the trial period.

An experimental vaccine is a type of vaccine developed from research that is intended for use in clinical trials and will not be marketed until approved by the relevant authorities. The vaccine is prepared by purifying the recombinant form of the novel coronavirus receptor binding protein (NCP-RBD) produced in CHO cells by adding aluminum hydroxide. The experimental vaccine used in this test has a specification of 25 μg / 0.5 ml / vial, which contains 25 μg NCP-RBD protein and 0.25 mg aluminum hydroxide adjuvant.

If the applicant chooses to participate in this study, the researcher will collect and fill in some personal information, including personal medical history, health conditions, and vaccines and medications that the volunteer uses.

Chinese vaccine against COVID-19 in Uzbekistan as of 23 December received 295 volunteers